At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With PNEUMOVAX™ 23 in Subjects 60 Years of Age and Older
In Brief
A Phase 3 clinical trial evaluating Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™, Comparator: placebo (concomitant-vaccine matched), and 1 other intervention for Herpes Zoster and Pneumococcal Infection. Completed, enrolled 473 participants.
Detailed Summary
The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are given alone, in adults 60 years of age and older.
Study Details
Timeline
Interventions
0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.